| 中文名称: | 雷尼酸锶 | ||||
|---|---|---|---|---|---|
| 英文名称: | Strontium Ranelate | ||||
| 别名: | 2,2'-((5-羧基-4-((羧甲基)-3-氰基噻吩-2-基)氮杂二基)二乙酸二锶盐 Distrontium renelate; S12911 | ||||
| CAS No: | 135459-87-9 | 分子式: | C12H6N2O8SSr2 | 分子量: | 513.49 |
| CAS No: | 135459-87-9 | ||||
| 分子式: | C12H6N2O8SSr2 | ||||
| 分子量: | 513.49 | ||||
| MDL: | MFCD09038742 | ||||
基本信息
|
产品编号： |
S10598 |
||||
|
产品名称： |
Strontium Ranelate |
||||
|
CAS: |
135459-87-9 |
储存条件 |
|
-20℃ |
四年 |
|
分子式： |
4℃ |
二年 |
|||
|
分子量： |
513.49 |
||||
|
化学名： |
2,2'-((5-羧基-4-((羧甲基)-3-氰基噻吩-2-基)氮杂二基)二乙酸二锶盐 Distrontium renelate |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
Insoluble |
|||
|
Ethanol |
Insoluble |
||||
|
Water |
Insoluble |
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
1.9475mL |
9.7373mL |
19.4746mL |
|
5mM |
0.3895mL |
1.9475mL |
3.8949mL |
|
10mM |
0.1947mL |
0.9737mL |
1.9475mL |
生物活性
|
产品描述 |
一种抗骨质疏松药物，其作用是通过减少骨吸收并促进骨形成，从而诱导正骨平衡。Strontium Ranelate 还可以激活非骨骼细胞中的钙敏感受体 (CaSR)，从而导致肌醇 1、4、5-三磷酸生成和丝裂原活化的蛋白激酶信号转导。 |
|
|
靶点 |
Calcium channel |
|
|
0.5mM |
||
|
体外研究 |
Strontium Ranelate (0.1-1mM;22 days;Mouse calvaria cells) treatment shows the expression of mRNA for early osteoblast markers (alkaline phosphatase,ALP) is visualized by day 5,while late markers (osteocalcin,OCN) are detectable only by day 15 and beyond.Strontium Ranelate (0.1-1mM;22 days;Mouse calvaria cells) treatment results in significantly increases the mRNA expression of the osteoblastic markers ALP,BSP and OCN at day 22 of MC cell culture.Strontium Ranelate is found to increase alkaline phosphatase activity and prostaglandin E2 production in a COX-2 dependent manner in murine marrow stromal cells. RT-PCR |
|
|
Cell Line: |
Mouse calvaria (MC) cells |
|
|
Concentration: |
0.1mM,0.3mM or 1mM |
|
|
Incubation Time: |
22 days |
|
|
Result: |
The expression of mRNA for early osteoblast markers (ALP) was visualized by day 5, while late markers (OCN) were detectable only by day 15 and beyond. |
|
|
Western Blot Analysis |
||
|
Cell Line: |
Mouse calvaria (MC) cells |
|
|
Concentration: |
0.1mM,0.3mM or 1mM |
|
|
Incubation Time: |
22 days |
|
|
Result: |
Significantly increased the mRNA expression of the osteoblastic markers ALP, BSP and OCN at day 22 of MC cell culture. |
|
|
体内研究 |
Strontium Ranelate increases bone formation and decreased bone resorption,which results in increased bone mass in the vertebrae of intact adult mice.In intact adult rats,Strontium Ranelate also increases bone mass,as measured by dual-energy X-ray absorptiometry,in lumbar vertebra and femur,and this is confirmed by histological assessment of trabecular bone volume in the tibial metaphysis.Strontium Ranelate is found to decrease bone resorption and to increase bone formation in alveolar bone in normal adult monkeys (Macaca fascicularis),which exhibits extensive bone remodeling.In ovariectomized rats, short-term (3 months) treatment with Strontium Ranelate prevents trabecular bone loss induced by oestrogen deficiency,as demonstrated by bone ash,bone mineral content and histomorphometric analysis in the tibial metaphysis.This effect results from decreased bone resorption while bone formation was maintained.These beneficial effects of Strontium Ranelate on bone mass and microarchitecture in ovariectomized rats are confirmed in long-term experiments. In this long-term study (2 years),the increase in bone mass and microarchitecture induced by Strontium Ranelate results in a marked improvement in bone strength, supporting the beneficial effect of this drug on bone resistance. |
|
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
